Merck & Co., Inc.
MRK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $17 | $16 | $16 | $16 |
| % Growth | 9.3% | 1.8% | -0.6% | – |
| Cost of Goods Sold | $3 | $4 | $3 | $4 |
| Gross Profit | $14 | $12 | $12 | $12 |
| % Margin | 81.9% | 77.5% | 78% | 75.5% |
| R&D Expenses | $4 | $4 | $4 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $6 | $7 |
| Operating Income | $8 | $6 | $6 | $4 |
| % Margin | 43.7% | 35.1% | 38.2% | 27.8% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$0 |
| Pre-Tax Income | $7 | $5 | $6 | $4 |
| Tax Expense | $1 | $1 | $1 | $0 |
| Net Income | $6 | $4 | $5 | $4 |
| % Margin | 33.5% | 28% | 32.7% | 24% |
| EPS | 2.32 | 1.77 | 2.02 | 1.48 |
| % Growth | 31.1% | -12.4% | 36.5% | – |
| EPS Diluted | 2.32 | 1.76 | 2.01 | 1.48 |
| Weighted Avg Shares Out | 2 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 2 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $8 | $6 | $7 | $6 |
| % Margin | 47.1% | 40.6% | 47.1% | 36.5% |